The Clínic Barcelona-IDIBAPS doctors excelled in their participation at the European Society of Medical Oncology (ESMO) Congress 2024, with the presentation of around 40 innovative studies in different areas of oncology.
More specifically, the studies focus on breast cancer (8), melanoma (6), lung cancer (6), brain cancel (4), head and neck cancer (4), liver cancer (2), anal cancer (1) and prostate cancer (1), epidemiology (1), nursing treatment (3) and phase 1 studies (1), which demonstrates the Campus Clínic’s leadership in clinical and translational research.
The Congress, held in Barcelona from 13 to 17 September, brought together over 30,000 professionals from all over the world to share the latest advances in cancer treatment. During the congress, 151 proffered papers, 207 mini-orals and 1,828 posters were presented.
Dr. Elias Campo, Director of IDIBAPS, values very positively the high participation of researchers at ESMO 2024 since it “reinforces our commitment to excellence in clinical and translational research, and the collaboration between our groups allowed for significant advances in cancer treatment that will have an impact on patient care”.
Presidential Symposium with Dr. Josep M. Llovet
One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was the presentation by Dr. Josep M. Llovet, head of the IDIBAPS Translational research in liver cancer group, Professor of Medicine at the University of Barcelona, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and ICREA Professor, at the Presidential Symposium. As principal investigator, Dr. Llovet presented the results of a phase 3 study of transarterial chemoembolization (TACE) with pembrolizumab and lenvatinib to treat advanced hepatocellular carcinoma. This study has the potential to change the treatment of liver cancer significantly and position combined therapies as a more effective option for patients with this aggressive disease.
Other outstanding contributions: abstracts and educational sessions
Moreover, researchers from the IDIBAPS Translational genomics and targeted therapies in solid tumours group led by Dr. Aleix Prat, who is also the director of the Hospital Clínic’s Institute of Cancer and Blood Disorders and Professor at the University of Barcelona, contributed with 27 abstracts at the congress, highlighting the important role played by the Clínic-IDIBAPS in precision oncology and the development of new therapeutic strategies to improve outcomes in patients with solid tumours.
In addition, the Clinic Barcelona-IDIBAPS team stood out in several educational sessions at the congress:
- Challenge Your Expert: Dr. Noemí Reguart participated in the session dedicated to escalation and de-escalation strategies with immunotherapies in non-small cell lung cancer (NSCLC).
- Educational: Dr. Laura Mezquita presented an educational session focusing on NSCLC, entitled: Oncogene-addicted earlier stage NSCLC: Current standards, debates, and open questions.
- Chairs: Drs. Ana Arance and Laura Mezquita participated as moderators in key sessions. Dr. Ana Arance focused on resistance to anti-PD-1 treatment in advanced melanoma, while Dr. Laura Mezquita moderated a session entitled: Promises and pitfalls in earlier stage NSCLC.
